102,995 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 102,995 shares of Ginkgo Bioworks Holdings, valued at approximately $587,000, representing 0.18% of the company.
• Ginkgo Bioworks reported a loss of $1.58 per share for the last quarter, missing the consensus estimate by $0.35, despite generating revenue of $48.32 million.
• The stock of Ginkgo Bioworks has seen a fifty-two week range from $5.00 to $16.85, with the current trading price around $12.18.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 102,995 shares of the company's stock, valued at approximately $587,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of Ginkgo Bioworks as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of DNA. Price T Rowe Associates Inc. MD raised its position in shares of Ginkgo Bioworks by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock valued at $814,000 after buying an additional 3,152 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Ginkgo Bioworks by 14.4% in the first quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company's stock valued at $150,000 after buying an additional 3,331 shares in the last quarter. Green Alpha Advisors LLC boosted its stake in shares of Ginkgo Bioworks by 31.7% during the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after acquiring an additional 4,449 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Ginkgo Bioworks in the fourth quarter valued at $46,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Ginkgo Bioworks by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock worth $412,000 after acquiring an additional 5,746 shares during the period. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded down $0.44 during midday trading on Wednesday, hitting $13.84. The company had a trading volume of 733,705 shares, compared to its average volume of 1,520,370. The stock has a market cap of $810.06 million, a PE ratio of -1.51 and a beta of 1.50. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.00 and a 1-year high of $16.85. The business's 50 day simple moving average is $10.33 and its two-hundred day simple moving average is $9.40.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The firm had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. On average, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.